What is the P/E ratio of Silo Pharma 2024?
The Silo Pharma P/E ratio is -1.23.
Own the gold standard ✨ in financial data & analytics fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news
Subscribe for $2 fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news
Overview
Profile
Silo Pharma stock price, quote, forecast and news stock price, forecast, news, chart, split, dividend and analysis Silo Pharma ariva, Silo Pharma onvista, Silo Pharma finanzen.net, Silo Pharma aktienfinder, Silo Pharma marketscreener, Silo Pharma marketwatch, Silo Pharma bloomberg, Silo Pharma handelsblatt, Silo Pharma wiwo, Silo Pharma forum
SILO
US82711P2011
Price
Price
1.02
Today +/-
-0.06
Today %
-6.18 %
TickerSILO
ISINUS82711P2011
P
Silo Pharma stock price
%
Weekly
Details
Price
ⓘOverview
The Quote Chart provides detailed and dynamic insights into the Silo Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.
Intraday Feature
The intraday feature provides real-time data, allowing investors to view the Silo Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.
Total Return and Relative Price Change
View the total return of the Silo Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.
Interpretation and Investment
Utilize the comprehensive data presented in the Quote Chart to analyze Silo Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.
Silo Pharma Stock Price History
| Date | Silo Pharma Price |
|---|---|
| 9/18/2024 | 1.02 undefined |
| 9/17/2024 | 1.09 undefined |
| 9/16/2024 | 1.10 undefined |
| 9/13/2024 | 1.10 undefined |
| 9/12/2024 | 1.08 undefined |
| 9/11/2024 | 1.17 undefined |
| 9/10/2024 | 1.07 undefined |
| 9/9/2024 | 1.23 undefined |
| 9/6/2024 | 1.20 undefined |
| 9/5/2024 | 1.20 undefined |
| 9/4/2024 | 1.13 undefined |
| 9/3/2024 | 1.10 undefined |
| 8/30/2024 | 1.17 undefined |
| 8/29/2024 | 1.20 undefined |
| 8/28/2024 | 1.23 undefined |
| 8/27/2024 | 1.42 undefined |
| 8/26/2024 | 1.39 undefined |
| 8/23/2024 | 1.45 undefined |
| 8/22/2024 | 1.40 undefined |
| 8/21/2024 | 1.40 undefined |
Silo Pharma Revenue, EBIT, Net Income US82711P2011 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Silo Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Silo Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Silo Pharma’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Silo Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Silo Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Silo Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Silo Pharma’s growth potential.
Silo Pharma Revenue, EBIT and net profit per share
| Date | Silo Pharma Revenue | Silo Pharma EBIT | Silo Pharma Net Income |
|---|---|---|---|
| 2029e | 73,440 undefined | 0 undefined | -6.81 M undefined |
| 2028e | 73,440 undefined | -39.05 M undefined | -5.53 M undefined |
| 2027e | 73,440 undefined | -26.94 M undefined | -5.12 M undefined |
| 2026e | 73,440 undefined | -17.15 M undefined | -3.29 M undefined |
| 2025e | 73,440 undefined | -9.57 M undefined | -3.2 M undefined |
| 2024e | 73,440 undefined | -4.56 M undefined | -2.56 M undefined |
| 2023 | 72,100 undefined | -3.86 M undefined | -3.7 M undefined |
| 2022 | 70,000 undefined | -3.63 M undefined | -3.91 M undefined |
| 2021 | 70,000 undefined | -2.75 M undefined | 2.5 M undefined |
| 2020 | 0 undefined | -2.2 M undefined | -3.11 M undefined |
| 2019 | 40,000 undefined | -900,000 undefined | -1.01 M undefined |
| 2018 | 0 undefined | -490,000 undefined | -970,000 undefined |
| 2017 | 20,000 undefined | -470,000 undefined | 360,000 undefined |
| 2016 | 50,000 undefined | -390,000 undefined | -1.11 M undefined |
| 2015 | 50,000 undefined | -220,000 undefined | -410,000 undefined |
| 2014 | 20,000 undefined | -250,000 undefined | -380,000 undefined |
| 2013 | 0 undefined | -70,000 undefined | 30,000 undefined |
| 2012 | 0 undefined | -40,000 undefined | -40,000 undefined |
| 2011 | 0 undefined | -50,000 undefined | -50,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2011 | 0 USD | -50,000 USD | -50,000 USD |
| 2012 | 0 USD | -40,000 USD | -40,000 USD |
| 2013 | 0 USD | -70,000 USD | 30,000 USD |
| 2014 | 20,000 USD | -250,000 USD | -380,000 USD |
| 2015 | 50,000 USD | -220,000 USD | -410,000 USD |
| 2016 | 50,000 USD | -390,000 USD | -1.11 M USD |
| 2017 | 20,000 USD | -470,000 USD | 360,000 USD |
| 2018 | 0 USD | -490,000 USD | -970,000 USD |
| 2019 | 40,000 USD | -900,000 USD | -1.01 M USD |
| 2020 | 0 USD | -2.2 M USD | -3.11 M USD |
| 2021 | 70,000 USD | -2.75 M USD | 2.5 M USD |
| 2022 | 70,000 USD | -3.63 M USD | -3.91 M USD |
| 2023 | 72,100 USD | -3.86 M USD | -3.7 M USD |
| 2024e | 73,440 USD | -4.56 M USD | -2.56 M USD |
| 2025e | 73,440 USD | -9.57 M USD | -3.2 M USD |
| 2026e | 73,440 USD | -17.15 M USD | -3.29 M USD |
| 2027e | 73,440 USD | -26.94 M USD | -5.12 M USD |
| 2028e | 73,440 USD | -39.05 M USD | -5.53 M USD |
| 2029e | 73,440 USD | 0 USD | -6.81 M USD |
Silo Pharma Income Statement, Balance Sheet, Cash Flow Statement
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | -2 | -3 | -3 | -4 | -9 | -17 | -26 | -39 | 0 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | -1 | -3 | 2 | -3 | -3 | -2 | -3 | -3 | -5 | -5 | -6 |
| - | - | - | - | - | - | - | - | - | 200.00 | -166.67 | -250.00 | - | -33.33 | 50.00 | - | 66.67 | - | 20.00 |
| 0.61 | 0.61 | 0.81 | 1.01 | 1.01 | 1 | 1 | 0.98 | 0.47 | 1.32 | 1.92 | 2.28 | 3.08 | 0 | 0 | 0 | 0 | 0 | 0 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Details
Keystats
ⓘRevenue and Growth
The Silo Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
Gross Margin
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT and EBIT Margin
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Income and Growth
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares Outstanding
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Interpreting Year to Year Comparison
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Expectations and Predictions
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Silo Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
Silo Pharma stock margins US82711P2011 ·
The Silo Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Silo Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Silo Pharma.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Silo Pharma's sales revenue. A higher gross margin percentage indicates that the Silo Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Silo Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Silo Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Silo Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Silo Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Silo Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Silo Pharma Margin History
| Silo Pharma Gross margin | Silo Pharma Profit margin | Silo Pharma EBIT margin | Silo Pharma Profit margin |
|---|---|---|---|
| 2029e | 91.9 % | 0 % | -9,271.11 % |
| 2028e | 91.9 % | -53,177.78 % | -7,528.89 % |
| 2027e | 91.9 % | -36,680.56 % | -6,968.89 % |
| 2026e | 91.9 % | -23,356.94 % | -4,480 % |
| 2025e | 91.9 % | -13,036.11 % | -4,355.56 % |
| 2024e | 91.9 % | -6,208.33 % | -3,484.44 % |
| 2023 | 91.9 % | -5,347.56 % | -5,132.7 % |
| 2022 | 100 % | -5,185.71 % | -5,585.71 % |
| 2021 | 100 % | -3,928.57 % | 3,571.43 % |
| 2020 | 91.9 % | 0 % | 0 % |
| 2019 | 25 % | -2,250 % | -2,525 % |
| 2018 | 91.9 % | 0 % | 0 % |
| 2017 | 91.9 % | -2,350 % | 1,800 % |
| 2016 | 91.9 % | -780 % | -2,220 % |
| 2015 | 91.9 % | -440 % | -820 % |
| 2014 | 91.9 % | -1,250 % | -1,900 % |
| 2013 | 91.9 % | 0 % | 0 % |
| 2012 | 91.9 % | 0 % | 0 % |
| 2011 | 91.9 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2011 | 91.9 % | 0 % | 0 % |
| 2012 | 91.9 % | 0 % | 0 % |
| 2013 | 91.9 % | 0 % | 0 % |
| 2014 | 91.9 % | -1,250 % | -1,900 % |
| 2015 | 91.9 % | -440 % | -820 % |
| 2016 | 91.9 % | -780 % | -2,220 % |
| 2017 | 91.9 % | -2,350 % | 1,800 % |
| 2018 | 91.9 % | 0 % | 0 % |
| 2019 | 25 % | -2,250 % | -2,525 % |
| 2020 | 91.9 % | 0 % | 0 % |
| 2021 | 100 % | -3,928.57 % | 3,571.43 % |
| 2022 | 100 % | -5,185.71 % | -5,585.71 % |
| 2023 | 91.9 % | -5,347.56 % | -5,132.7 % |
| 2024e | 91.9 % | -6,208.33 % | -3,484.44 % |
| 2025e | 91.9 % | -13,036.11 % | -4,355.56 % |
| 2026e | 91.9 % | -23,356.94 % | -4,480 % |
| 2027e | 91.9 % | -36,680.56 % | -6,968.89 % |
| 2028e | 91.9 % | -53,177.78 % | -7,528.89 % |
| 2029e | 91.9 % | 0 % | -9,271.11 % |
Silo Pharma Stock Sales Revenue, EBIT, Earnings per Share US82711P2011 ·
The Silo Pharma earnings per share therefore indicates how much revenue Silo Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
3 years
5 years
10 years
25 Years
Max
Sales per Share
EBIT per share
Earnings per Share
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Silo Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Silo Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Silo Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Silo Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Silo Pharma Revenue, EBIT and net profit per share
| Date | Silo Pharma Sales per Share | Silo Pharma EBIT per share | Silo Pharma Earnings per Share |
|---|---|---|---|
| 2029e | 0.02 undefined | 0 undefined | -1.52 undefined |
| 2028e | 0.02 undefined | 0 undefined | -1.23 undefined |
| 2027e | 0.02 undefined | 0 undefined | -1.14 undefined |
| 2026e | 0.02 undefined | 0 undefined | -0.73 undefined |
| 2025e | 0.02 undefined | 0 undefined | -0.71 undefined |
| 2024e | 0.02 undefined | 0 undefined | -0.57 undefined |
| 2023 | 0.02 undefined | -1.25 undefined | -1.2 undefined |
| 2022 | 0.03 undefined | -1.59 undefined | -1.71 undefined |
| 2021 | 0.04 undefined | -1.43 undefined | 1.3 undefined |
| 2020 | 0 undefined | -1.67 undefined | -2.36 undefined |
| 2019 | 0.09 undefined | -1.91 undefined | -2.15 undefined |
| 2018 | 0 undefined | -0.5 undefined | -0.99 undefined |
| 2017 | 0.02 undefined | -0.47 undefined | 0.36 undefined |
| 2016 | 0.05 undefined | -0.39 undefined | -1.11 undefined |
| 2015 | 0.05 undefined | -0.22 undefined | -0.41 undefined |
| 2014 | 0.02 undefined | -0.25 undefined | -0.38 undefined |
| 2013 | 0 undefined | -0.09 undefined | 0.04 undefined |
| 2012 | 0 undefined | -0.07 undefined | -0.07 undefined |
| 2011 | 0 undefined | -0.08 undefined | -0.08 undefined |
| Sales per Share | EBIT per share | Earnings per Share | |
|---|---|---|---|
| 2011 | 0 USD | -0.08 USD | -0.08 USD |
| 2012 | 0 USD | -0.07 USD | -0.07 USD |
| 2013 | 0 USD | -0.09 USD | 0.04 USD |
| 2014 | 0.02 USD | -0.25 USD | -0.38 USD |
| 2015 | 0.05 USD | -0.22 USD | -0.41 USD |
| 2016 | 0.05 USD | -0.39 USD | -1.11 USD |
| 2017 | 0.02 USD | -0.47 USD | 0.36 USD |
| 2018 | 0 USD | -0.5 USD | -0.99 USD |
| 2019 | 0.09 USD | -1.91 USD | -2.15 USD |
| 2020 | 0 USD | -1.67 USD | -2.36 USD |
| 2021 | 0.04 USD | -1.43 USD | 1.3 USD |
| 2022 | 0.03 USD | -1.59 USD | -1.71 USD |
| 2023 | 0.02 USD | -1.25 USD | -1.2 USD |
| 2024e | 0.02 USD | 0 USD | -0.57 USD |
| 2025e | 0.02 USD | 0 USD | -0.71 USD |
| 2026e | 0.02 USD | 0 USD | -0.73 USD |
| 2027e | 0.02 USD | 0 USD | -1.14 USD |
| 2028e | 0.02 USD | 0 USD | -1.23 USD |
| 2029e | 0.02 USD | 0 USD | -1.52 USD |
Silo Pharma business model
Silo Pharma is one of the most popular companies on Eulerpool.com.
Silo Pharma Eulerpool Fair Value
Details
Fair Value
ⓘUnderstanding Fair Value
The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.
Income-Based Fair Value
This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.
Example 2022
Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)
Revenue-Based Fair Value
It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.
Example 2022
Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)
Dividend-Based Fair Value
This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.
Example 2022
Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)
Expectations and Forecasts
Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.
Comparative Analysis
Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.
Silo Pharma historical P/E ratio, EBIT, and P/S ratio.
Silo Pharma shares outstanding US82711P2011 ·
The number of shares was Silo Pharma in 2023 — This indicates how many shares 3.08 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Silo Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Silo Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Silo Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Silo Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2011 | 610,000 Aktien |
| 2012 | 610,000 Aktien |
| 2013 | 810,000 Aktien |
| 2014 | 1.01 M Aktien |
| 2015 | 1.01 M Aktien |
| 2016 | 1 M Aktien |
| 2017 | 1 M Aktien |
| 2018 | 980,000 Aktien |
| 2019 | 470,000 Aktien |
| 2020 | 1.32 M Aktien |
| 2021 | 1.92 M Aktien |
| 2022 | 2.28 M Aktien |
| 2023 | 3.08 M Aktien |
| 2024e | 3.08 M Aktien |
| 2025e | 3.08 M Aktien |
| 2026e | 3.08 M Aktien |
| 2027e | 3.08 M Aktien |
| 2028e | 3.08 M Aktien |
| 2029e | 3.08 M Aktien |
Silo Pharma Stock splits
In Silo Pharma's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Silo Pharma.
Silo Pharma latest earnings and earnings surprises
| Date | EPS Estimate | EPS Actual | Quarterly report |
|---|---|---|---|
| 12/31/2023 | -0.2 | -0.36 (-76.47 %) | 2023 Q4 |
1
Silo Pharma list of shareholders
% | Name | Stocks | Change | Date |
|---|---|---|---|---|
| 3.91589 % | Weisblum (Eric) | 175,432 | 2,100 | 4/5/2024 |
| 1.40194 % | Financial Advocates Investment Management | 62,807 | 5,500 | 12/31/2023 |
| 0.73310 % | UBS Financial Services, Inc. | 32,843 | 32,843 | 12/31/2023 |
| 0.36460 % | The Vanguard Group, Inc. | 16,334 | 1,830 | 12/31/2023 |
| 0.36114 % | Geode Capital Management, L.L.C. | 16,179 | 0 | 12/31/2023 |
| 0.28545 % | Two Sigma Investments, LP | 12,788 | 12,788 | 12/31/2023 |
| 0.27902 % | State Street Global Advisors (US) | 12,500 | 0 | 12/31/2023 |
| 0.15641 % | Tower Research Capital LLC | 7,007 | 2,117 | 12/31/2023 |
| 0.11161 % | Ryweck (Daniel E.) | 5,000 | 0 | 3/23/2024 |
| 0.00210 % | Westside Investment Management, LLC | 94 | 0 | 3/31/2024 |
1
2
Silo Pharma Executives and Management Board
Mr. Eric Weisblum53
Silo Pharma Chairman of the Board, President, Chief Executive Officer (since 2013)
Compensation 322,500
Mr. Wayne Linsley67
Silo Pharma Independent Director
Compensation 60,112
Dr. Kevin Munoz44
Silo Pharma Independent Director
Compensation 40,112
Mr. Daniel Ryweck59
Silo Pharma Chief Financial Officer
Compensation 15,000
Dr. Jeff Pavell56
Silo Pharma Independent Director
1
Most common questions regarding Silo Pharma
What is the P/S ratio of Silo Pharma 2024?
The Silo Pharma P/S ratio is 42.78.
What is the AlleAktien quality score of Silo Pharma?
The AlleAktien quality score for Silo Pharma is 4/10.
What is the revenue of Silo Pharma 2024?
The expected Silo Pharma revenue is 73,440 USD.
How high is the profit of Silo Pharma 2024?
The expected Silo Pharma profit is -2.56 M USD.
What is the business model of Silo Pharma
No history available for Silo Pharma.
What is the Silo Pharma dividend?
Silo Pharma pays a dividend of 0 USD distributed over payouts per year.
How often does Silo Pharma pay dividends?
The dividend cannot currently be calculated for Silo Pharma or the company does not pay out a dividend.
What is the Silo Pharma ISIN?
The ISIN of Silo Pharma is US82711P2011.
What is the Silo Pharma ticker?
The ticker of Silo Pharma is SILO.
How much dividend does Silo Pharma pay?
Over the past 12 months, Silo Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Silo Pharma is expected to pay a dividend of 0 USD.
What is the dividend yield of Silo Pharma?
The current dividend yield of Silo Pharma is .
When does Silo Pharma pay dividends?
Silo Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Silo Pharma?
Silo Pharma paid dividends every year for the past 0 years.
What is the dividend of Silo Pharma?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Silo Pharma located?
Silo Pharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von Silo Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Silo Pharma from 9/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/19/2024.
When did Silo Pharma pay the last dividend?
The last dividend was paid out on 9/19/2024.
What was the dividend of Silo Pharma in the year 2023?
In the year 2023, Silo Pharma distributed 0 USD as dividends.
In which currency does Silo Pharma pay out the dividend?
The dividends of Silo Pharma are distributed in USD.
Silo Pharma stock price, news, forecast, analysis
Sector
Health
Industry
Biotechnology
Number of shares
Employee
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website Silo Pharma
Country
United States of America 🇺🇸
Currency
USD
Initial public offering
Jan 5, 2012
GOSIN
Global Open Securities Identification Number
Cusip
82711P201
Market capitalization
PEG
-0.05
P/E
Forward P/E
-1.79
P/S
Forward P/S
42.78
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC
Scalable Capital savings plan Nein
Trade Republic savings plan Nein
comdirect savings plan
Consorsbank savings plan Nein
ING savings plan Nein
Silo Pharma Peer Group
Silo Pharma Eulerpool News
Silo Pharma News
Silo Pharma FIGI
| Silo Pharma Ticker | Silo Pharma FIGI |
|---|---|
| SILO:US | BBG002D1DZ06 |
| SILO:UA | BBG002D1DZ15 |
| SILO:UC | BBG002D1DZ24 |
| SILO:UN | BBG002D1DZ42 |
| SILO:UP | BBG002D1DZ51 |
| SILO:UB | BBG002D1DZ79 |
| SILO:UM | BBG002D1DZ97 |
| SILO:UX | BBG002D1DZB4 |
| SILO:UR | BBG002D1DZC3 |
| SILO:UD | BBG002D1DZJ6 |
| SILO:UF | BBG002D1DZM2 |
| SILO:VY | BBG002D1DZN1 |
| SILO:VJ | BBG002D1DZP9 |
| SILO:VK | BBG002D1DZQ8 |
| SILO:VF | BBG00DJGVM66 |
All fundamentals about Silo Pharma
Our stock analysis for Silo Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Silo Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.